LENSAR, Inc.
HealthcareNASDAQ:LNSR · NASDAQ Capital Market
+$0.00 today
Vol 0.03M · Avg 0.12M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$57.7M of revenue converted into $29.4M of net income for the selected period. Gross margin is 45.4% and net margin is 55.7%, showing how much revenue survives after costs and taxes. EPS is $-0.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58.4M +9.2% | $53.5M +26.9% | $42.2M +19.2% | $35.4M +2.6% | $34.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $31.3M +13.3% | $27.6M +31.3% | $21.1M +36.7% | $15.4M -7.4% | $16.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $27.1M +4.9% | $25.9M +22.5% | $21.1M +5.8% | $20.0M +11.9% | $17.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 46.4% -1.9pp | 48.3% -1.7pp | 50.1% -6.4pp | 56.4% +4.7pp | 51.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $5.6M +5.5% | $5.3M -13.2% | $6.1M -48.0% | $11.8M -4.4% | $12.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $45.2M +70.5% | $26.5M +1.5% | $26.1M -3.9% | $27.2M +13.7% | $23.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $51.7M +41.6% | $36.5M +9.5% | $33.3M -16.9% | $40.1M +7.1% | $37.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.5M +14.5% | $3.9M +11.8% | $3.5M +3.2% | $3.4M +23.2% | $2.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$29.8M -890.9% | -$3.0M +72.4% | -$10.9M +34.2% | -$16.5M +2.0% | -$16.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -51.0% -45.3pp | -5.6% +20.2pp | -25.8% +20.9pp | -46.7% +2.2pp | -48.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$24.6M -130.5% | -$10.7M +12.8% | -$12.2M +39.4% | -$20.2M -2.7% | -$19.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -42.1% -22.1pp | -19.9% +9.1pp | -29.0% +28.1pp | -57.1% -0.0pp | -57.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $91.0K -11.7% | $103.0K +21.2% | $85.0K +400.0% | $17.0K -50.0% | $34.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$9.7M +53.2% | -$20.7M -862.8% | -$2.2M -919.0% | $263.0K +415.7% | $51.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$34.3M -9.2% | -$31.4M -118.3% | -$14.4M +27.8% | -$19.9M -1.6% | -$19.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -58.7% +0.0pp | -58.7% -24.6pp | -34.1% +22.2pp | -56.3% +0.6pp | -56.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$34.3M -9.2% | -$31.4M -118.3% | -$14.4M +27.8% | -$19.9M -1.6% | -$19.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -58.7% +0.0pp | -58.7% -24.6pp | -34.1% +22.2pp | -56.3% +0.6pp | -56.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -5.1% | -$3 -108.4% | -$1 +33.2% | -$2 +6.7% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -5.1% | -$3 -108.4% | -$1 +33.2% | -$2 +6.7% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $12.0M +3.8% | $11.5M +5.0% | $11.0M +8.0% | $10.2M +8.4% | $9.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $12.0M +3.8% | $11.5M +5.0% | $11.0M +8.0% | $10.2M +8.4% | $9.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Owlet, Inc.
NYSE:OWLT
$84.14M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Accuray Incorporated
ARAY
$40.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LNSR generate?
LENSAR, Inc. (LNSR) reported $58.44M of revenue in fiscal 2025.
Is LNSR profitable?
LENSAR, Inc. (LNSR) reported -$34,280,000.00 of net income, with a net margin of -58.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.